These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
350 related articles for article (PubMed ID: 26852651)
1. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. Taher AT; Cappellini MD; Aydinok Y; Porter JB; Karakas Z; Viprakasit V; Siritanaratkul N; Kattamis A; Wang C; Zhu Z; Joaquin V; Uwamahoro MJ; Lai YR Blood Cells Mol Dis; 2016 Mar; 57():23-9. PubMed ID: 26852651 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. Porter JB; Elalfy MS; Taher AT; Aydinok Y; Chan LL; Lee SH; Sutcharitchan P; Habr D; Martin N; El-Beshlawy A Ann Hematol; 2013 Jan; 92(2):211-9. PubMed ID: 23086508 [TBL] [Abstract][Full Text] [Related]
3. Deferasirox for managing iron overload in people with thalassaemia. Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446 [TBL] [Abstract][Full Text] [Related]
5. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Taher A; El-Beshlawy A; Elalfy MS; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Hmissi A; Al Jefri A Eur J Haematol; 2009 Jun; 82(6):458-65. PubMed ID: 19187278 [TBL] [Abstract][Full Text] [Related]
7. Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients. Taher AT; Porter JB; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Galanello R; Karakas Z; Lawniczek T; Habr D; Ros J; Zhang Y; Cappellini MD Am J Hematol; 2013 Jun; 88(6):503-6. PubMed ID: 23553596 [TBL] [Abstract][Full Text] [Related]
10. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia. Taher AT; Porter JB; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Origa R; Karakas Z; Habr D; Zhu Z; Cappellini MD Br J Haematol; 2015 Jan; 168(2):284-90. PubMed ID: 25212456 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of Deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial. Lai YR; Liu RR; Li CF; Huang SL; Li Q; Habr D; Martin N; Shen ZX Transfus Med; 2013 Dec; 23(6):389-96. PubMed ID: 24147622 [TBL] [Abstract][Full Text] [Related]
12. Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassaemia. Chuansumrit A; Pengpis P; Mahachoklertwattana P; Sirachainan N; Poomthavorn P; Sungkarat W; Kadegasem P; Khlairit P; Wongwerawattanakoon P Acta Haematol; 2017; 137(1):20-26. PubMed ID: 27838686 [TBL] [Abstract][Full Text] [Related]
13. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793 [TBL] [Abstract][Full Text] [Related]
14. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia. Porter JB; Elalfy M; Taher A; Aydinok Y; Lee SH; Sutcharitchan P; El-Ali A; Han J; El-Beshlawy A Eur J Haematol; 2017 Mar; 98(3):280-288. PubMed ID: 27859648 [TBL] [Abstract][Full Text] [Related]
15. Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. Pennell DJ; Porter JB; Piga A; Lai YR; El-Beshlawy A; Elalfy M; Yesilipek A; Kilinç Y; Habr D; Musallam KM; Shen J; Aydinok Y; Am J Hematol; 2015 Feb; 90(2):91-6. PubMed ID: 25345697 [TBL] [Abstract][Full Text] [Related]
16. Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia. Shirley M; Plosker GL Drugs; 2014 Jun; 74(9):1017-27. PubMed ID: 24919862 [TBL] [Abstract][Full Text] [Related]
17. Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies. Fragomeno C; Roccabruna E; D'Ascola DG Blood Cells Mol Dis; 2015 Dec; 55(4):382-6. PubMed ID: 26460263 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran. Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712 [TBL] [Abstract][Full Text] [Related]
19. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study). Ho PJ; Tay L; Teo J; Marlton P; Grigg A; St Pierre T; Brown G; Badcock CA; Traficante R; Gervasio OL; Bowden DK Eur J Haematol; 2017 Feb; 98(2):97-105. PubMed ID: 27537786 [TBL] [Abstract][Full Text] [Related]
20. Deferasirox for managing iron overload in people with thalassaemia. Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]